Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in
non-small-cell lung cancer (NSCLC), particularly in tumors of adenocarcinoma (ADC) …

Lung cancer is the leading cause of death for malignancy worldwide. Its molecular profiling
has enriched our understanding of cancer initiation and progression and has become …

Objective To establish evidence-based recommendations for the molecular analysis of lung
cancers that are that are required to guide EGFR-and ALK-directed therapies, addressing …

Lung cancer is the leading cause of cancer-related mortality. While the majority of lung
cancers are associated with tobacco smoke, approximately 10–15% of US lung cancers …

To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The Second …

Aldehyde dehydrogenase (ALDH) is a candidate marker for lung cancer cells with stem cell-
like properties. Immunohistochemical staining of a large panel of primary non–small cell …

Background Epidermal growth factor receptor exon 20 insertion (EGFRex20ins) mutations
represent approximately 4–12% of EGFR mutations and are generally refractory to the 1st …

Clinical biomarker tests that aid in making treatment decisions will play an important role in
achieving personalized medicine for cancer patients. Definitive evaluation of the clinical …

Background A fusion gene between echinoderm microtubule-associated protein-like 4
(EML4) and the anaplastic lymphoma kinase (ALK) has recently been identified in non-small …

Lung cancer still contributes to nearly one‐quarter cancer‐related deaths in the past
decades, despite the rapid development of targeted therapy and immunotherapy in non …